Anogenital human papillomavirus infection

This Phase 3 trial tests a 9-valent HPV vaccine in over 9,000 healthy women aged 18-45. The vaccine targets nine HPV types linked to cervical cancer and genital warts. Researchers compare it to an existing 2-valent vaccine to see if it provides broader protection. The goal is to …

This early-stage study tests a new treatment called T-Plex for people with advanced solid tumors (like head and neck, cervical, or melanoma) that haven't responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to recognize and…

Researchers are tracking HPV-16 and HPV-18 neutralizing antibodies in females who received a bivalent HPV vaccine in an earlier study. Participants were 9 to 26 years old when first vaccinated and received either two or three doses. No vaccine is given in this extension. Blood sa…

This completed study examined 217 Hispanic people living with HIV in California, Mexico, and Puerto Rico to see if the types of bacteria in the anus are linked to high-risk HPV infection and pre-cancerous lesions. Researchers collected anal swabs and questionnaires to compare mic…

This study looks at how the immune system of patients in the intensive care unit (ICU) responds to severe infections caused by viruses or bacteria. Researchers will take extra blood samples from 38 adults to analyze immature granulocytes, a type of immune cell. The goal is to see…

This study explores whether transgender individuals can collect their own samples for HPV testing at home or in a clinic. Researchers want to learn how common high-risk HPV is in this group and whether self-sampling is acceptable and effective. About 100 transgender men and women…